These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33808045)

  • 21. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
    Geng Y; Faber KN; de Meijer VE; Blokzijl H; Moshage H
    Hepatol Int; 2021 Feb; 15(1):21-35. PubMed ID: 33548031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway.
    Li M; Xu C; Shi J; Ding J; Wan X; Chen D; Gao J; Li C; Zhang J; Lin Y; Tu Z; Kong X; Li Y; Yu C
    Gut; 2018 Dec; 67(12):2169-2180. PubMed ID: 28877979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways.
    Wu X; Zhang L; Gurley E; Studer E; Shang J; Wang T; Wang C; Yan M; Jiang Z; Hylemon PB; Sanyal AJ; Pandak WM; Zhou H
    Hepatology; 2008 Jun; 47(6):1905-15. PubMed ID: 18452148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study on the state of macrophage infiltration in the progression of non-alcoholic fatty liver disease induced by high-fat diet in mice].
    Zhong L; Xu KS; Deng L
    Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):1042-1047. PubMed ID: 34865353
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
    Xi Y; Li H
    Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver.
    Ramos LF; Silva CM; Pansa CC; Moraes KCM
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):25-40. PubMed ID: 32892668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
    Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
    Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Shi Y; Pizzini J; Wang H; Das F; Abdul Azees PA; Ghosh Choudhury G; Barnes JL; Zang M; Weintraub ST; Yeh CK; Katz MS; Kamat A
    Am J Physiol Endocrinol Metab; 2021 Jul; 321(1):E90-E104. PubMed ID: 34029162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity induced Ext1 reduction mediates the occurrence of NAFLD.
    Wang M; Li B; Qin F; Ye J; Jin L
    Biochem Biophys Res Commun; 2022 Jan; 589():123-130. PubMed ID: 34906902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatty Acids Activate the Transcriptional Coactivator YAP1 to Promote Liver Fibrosis via p38 Mitogen-Activated Protein Kinase.
    Salloum S; Jeyarajan AJ; Kruger AJ; Holmes JA; Shao T; Sojoodi M; Kim MH; Zhuo Z; Shroff SG; Kassa A; Corey KE; Khan SK; Lin W; Alatrakchi N; Schaefer EAK; Chung RT
    Cell Mol Gastroenterol Hepatol; 2021; 12(4):1297-1310. PubMed ID: 34118488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats.
    Liu J; Han L; Zhu L; Yu Y
    Lipids Health Dis; 2016 Feb; 15():27. PubMed ID: 26868515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human germline hedgehog pathway mutations predispose to fatty liver.
    Guillen-Sacoto MJ; Martinez AF; Abe Y; Kruszka P; Weiss K; Everson JL; Bataller R; Kleiner DE; Ward JM; Sulik KK; Lipinski RJ; Solomon BD; Muenke M
    J Hepatol; 2017 Oct; 67(4):809-817. PubMed ID: 28645738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver sympathetic denervation reverses obesity-induced hepatic steatosis.
    Hurr C; Simonyan H; Morgan DA; Rahmouni K; Young CN
    J Physiol; 2019 Sep; 597(17):4565-4580. PubMed ID: 31278754
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Bae S; Lee YH; Lee J; Park J; Jun W
    Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558538
    [No Abstract]   [Full Text] [Related]  

  • 36. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
    Wu YK; Ren ZN; Zhu SL; Wu YZ; Wang G; Zhang H; Chen W; He Z; Ye XL; Zhai QX
    Acta Pharmacol Sin; 2022 Jun; 43(6):1473-1483. PubMed ID: 34654875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early onset and progression of non-alcoholic fatty liver disease in young monosodium l-glutamate-induced obese mice.
    Coelho CFF; França LM; Nascimento JR; Dos Santos AM; Azevedo-Santos APS; Nascimento FRF; Paes AMA
    J Dev Orig Health Dis; 2019 Apr; 10(2):188-195. PubMed ID: 29855396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.
    Pafili K; Roden M
    Mol Metab; 2021 Aug; 50():101122. PubMed ID: 33220492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.
    Monteillet L; Gjorgjieva M; Silva M; Verzieux V; Imikirene L; Duchampt A; Guillou H; Mithieux G; Rajas F
    Mol Metab; 2018 Oct; 16():100-115. PubMed ID: 30100243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.